Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Payables (2016 - 2025)

Historic Payables for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $646000.0.

  • CytomX Therapeutics' Payables fell 5457.1% to $646000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $646000.0, marking a year-over-year decrease of 5457.1%. This contributed to the annual value of $1.1 million for FY2024, which is 2537.72% down from last year.
  • Per CytomX Therapeutics' latest filing, its Payables stood at $646000.0 for Q3 2025, which was down 5457.1% from $227000.0 recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Payables high stood at $5.2 million for Q3 2022, and its period low was $227000.0 during Q2 2025.
  • For the 5-year period, CytomX Therapeutics' Payables averaged around $1.7 million, with its median value being $1.7 million (2023).
  • Per our database at Business Quant, CytomX Therapeutics' Payables surged by 24142.48% in 2022 and then plummeted by 8594.7% in 2025.
  • Over the past 5 years, CytomX Therapeutics' Payables (Quarter) stood at $2.8 million in 2021, then fell by 0.32% to $2.8 million in 2022, then crashed by 48.1% to $1.5 million in 2023, then dropped by 25.38% to $1.1 million in 2024, then plummeted by 40.62% to $646000.0 in 2025.
  • Its Payables stands at $646000.0 for Q3 2025, versus $227000.0 for Q2 2025 and $276000.0 for Q1 2025.